A new process for the synthesis of anticancer drug lenalidomide was developed, using platinum group metal-free and efficient reduction of nitro group with the iron powder and ammonium chloride. It was found that the bromination of the key raw material, methyl 2-methyl-3-nitrobenzoate, could be carried out in chlorine-free solvent methyl acetate without forming significant amounts of hazardous by-products. We also have compared the known synthetic methods for cyclization of methyl 2-(bromomethyl)-3-nitrobenzoate and 3-aminopiperidinedione to form lenalidomide nitro precursor.
Similar content being viewed by others
References
Singhal, S.; Mehta, J.; Desikan, R.; Ayers, D.; Roberson, P.; Eddlemon, P.; Munshi, N.; Anaissie, E.; Wilson, C.; Dhodapkar, M.; Zeldis, J.; Siegel, D.; Crowley, J.; Barlogie, B. N. Engl. J. Med. 1999, 341, 1565.
Raje, N.; Anderson, K. N. Engl. J. Med. 1999, 341, 1606.
Little, R. F.; Wyvill, K. M.; Pluda, J. M.; Welles, L.; Marshall, V.; Figg, W. D.; Newcomb, F. M.; Tosato, G.; Feigal, E.; Steinberg, S. M.; Whitby, D.; Goedert, J. J.; Yarchoan, R. J. Clin. Oncol. 2000, 18, 2593.
Eisen, T.; Boshoff, C.; Mak, I.; Sapunar, F.; Vaughan, M. M.; Pyle, L.; Johnston, S. R.; Ahern, R.; Smith, I. E.; Gore, M. E. Br. J. Cancer 2000, 82, 812.
Chen, M.; Doherty, S.; Hsu, D. S. Dermatol. Clin. 2010, 3, 577.
Palumbo, A.; Hajek, R.; Delforge, M.; Kropff, M.; Petrucci, M. T.; Catalano, J.; Gisslinger, H.; Wiktor-Jędrzejczak, W.; Zodelava, M.; Weisel, K.; Cascavilla, N.; Iosava, G.; Cavo, M.; Kloczko, J.; Bladé, J.; Beksac, M.; Spicka, I.; Plesner, T.; Radke, J.; Langer, C.; Ben Yehuda, D.; Corso, A.; Herbein, L.; Yu, Z.; Mei, J.; Jacques, C.; Dimopoulos, M. A. N. Engl. J. Med. 2012, 366, 1759.
Aue, G.; Njuguna, N.; Tian, X.; Soto, S.; Hughes, T.; Vire, B.; Keyvanfar, K.; Gibellini, F.; Valdez, J.; Boss, C.; Samsel, L.; McCoy, J. P., Jr.; Wilson, W. H.; Pittaluga, S.; Wiestner, A. Haematologica 2009, 94(9), 1266.
Jagtap, P. G.; Southan, G. J.; Baloglu, E.; Ram, S.; Mabley, J. G.; Marton, A.; Salzman, A.; Szabó, C. Bioorg. Med. Chem. Lett. 2004, 14(1), 81.
Shah, J. H.; Connery, B. P.; Swartz, G. M.; Hunsucker, K. A.; Rougas, J.; D'Amato, R. J.; Pribluda, V.; Treston, A. US Patent 2003139451.
Konakanchi, D. P.; Gongalla, B.; Sikha, K. B.; Kandaswamy, C.; Adibhatla, K. S. B. R.; Nannapaneni, V. C. WO Patent 2011111053.
Yan, R.; Yang, H.; Xu, Y. WO Patent 2010139266.
Siegel, J. S.; Weber, B. WO Patent 2005005409.
Muller, G. W.; Chen, R.; Huang, S. Y.; Corral, L. G.; Wong, L. M.; Patterson, R. T.; Chen, Y.; Kaplan, G.; Stirling, D. I. Bioorg. Med. Chem. Lett. 1999, 9(11), 1625.
Deng, Z.; Chen, F.; Jiang, J.; CN Patent 103601717.
Wang, X.; Li, J.; Yao, Q. CN Patent 102838586.
Chaulet, C.; Croix, C.; Alagille, D.; Normand, S.; Delwail, A.; Favot, L.; Lecron, J.-C.; Viaud-Massuard, M.-C. Bioorg. Med. Chem. Lett. 2011, 21(3), 1019.
Balaev, A. N.; Okhmanovich, K. A.; Fedorov, V. E. Pharm. Chem. J. 2013, 46(11), 676. [Khim.-Farm. Zh. 2012, 46(11), 34.]
Song, Y.-L.; Jiang, L.-L.; Wang, X-.H.; Meng, Y.-Q. Zhongguo Xinyao Zazhi 2011, 20, 75.
Greig, N. H.; Luo, W.; Tweedie, D.; Holloway, H. W.; Yu, Q.-S.; Goetzl, E. J. US Patent 2013143922.
Stiegel, H.-H.; Albrecht, W.; Brueck, S.; Paetz, J. M. D. WO Patent 2011050962.
This work was performed in accordance with marketoriented study ''Development of technology for cytostatic and immunomodulating drugs preparation'' with financial support from Ministry of Education and Science of the Republic of Latvia, JSC ''Grindex'', and Latvian Institute of Organic Synthesis. The authors also wish to acknowledge the financial support of the InnovaBalt (Latvian Institute of Organic Synthesis) project.
The authors are grateful to Anatoly Mishnev (Latvian Institute of Organic Synthesis) for determination of polymorphic forms.
Author information
Authors and Affiliations
Corresponding author
Additional information
Published in Khimiya Geterotsiklicheskikh Soedinenii, 2015, 51(2), 133–138
Rights and permissions
About this article
Cite this article
Ponomaryov, Y., Krasikova, V., Lebedev, A. et al. Scalable and green process for the synthesis of anticancer drug lenalidomide. Chem Heterocycl Comp 51, 133–138 (2015). https://doi.org/10.1007/s10593-015-1670-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10593-015-1670-0